

**WHAT IS CLAIMED:**

1. A method of preventing or treating Alzheimer's Disease in a subject comprising:  
5 administering to the subject an agent which inhibits interaction between amyloid- $\beta$  and proteins which chaperone amyloid- $\beta$  under conditions effective to prevent or treat Alzheimer's Disease in the subject.
2. The method according to claim 1, wherein the protein which  
10 chaperones amyloid- $\beta$  is  $\alpha$ -chymotrypsin.
3. The method according to claim 1, wherein the protein which chaperones amyloid- $\beta$  is apolipoprotein E.
- 15 4. The method according to claim 3, wherein the agent is a protein or a peptidomimetic.
5. The method according to claim 4, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.  
20
6. The method according to claim 1, wherein the agent has a three dimensional structure like that of a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.
- 25 7. The method according to claim 1, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.
8. The method according to claim 1, wherein the agent is a protein  
30 comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

9. The method according to claim 1, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

5 10. The method according to claim 1, wherein Alzheimer's Disease is prevented.

11. The method according to claim 1, wherein Alzheimer's Disease is treated.  
10

12. A method of inhibiting accumulation of amyloid- $\beta$  deposits in a subject's brain comprising:  
administering to the subject an agent which inhibits interaction between amyloid- $\beta$  and proteins which chaperone amyloid- $\beta$  under conditions effective to inhibit accumulation of amyloid- $\beta$  deposits in the subject's brain.  
15

13. The method according to claim 12, wherein the protein which chaperones amyloid- $\beta$  is  $\alpha$ -chymotrypsin.

20 14. The method according to claim 12, wherein the protein which chaperones amyloid- $\beta$  is apolipoprotein E.

15. The method according to claim 12, wherein the agent is a protein or a peptidomimetic.  
25

16. The method according to claim 15, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 2 or 3.

17. The method according to claim 12, wherein the agent has a three dimensional structure like that of a protein comprising an amino acid sequence of SEQ ID NOs: 2 or 3.  
30

18. The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

5 19. The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

20. The method according to claim 12, wherein said administering is  
10 carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

21. A method of inhibiting interaction between apolipoprotein E and amyloid- $\beta$  comprising:  
15 administering an agent which blocks interaction of apolipoprotein E and amyloid- $\beta$  under conditions effect to block such interaction.

22. The method according to claim 21, wherein the agent is a protein or a peptidomimetic.  
20

23. The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

24. The method according to claim 21, wherein the agent has a three  
25 dimensional structure like that of a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

25. The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of  
30 SEQ ID NOs: 3 or 4.

26. The method according to claim 21, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.